Teva Can't Dodge GSK's Wellbutrin False Ad Suit

Law360, New York (March 10, 2014, 8:45 PM EDT) -- A Pennsylvania federal judge refused Monday to dismiss GlaxoSmithKline LLC's lawsuit accusing Teva Pharmaceuticals USA Inc. of falsely advertising a generic antidepressant as equivalent to GSK's brand-name version, saying it was not preempted by a past U.S. Food and Drug Administration finding.

GSK is accusing Teva of damaging its reputation and endangering consumer health by promoting the generic Budeprion XL as having the same therapeutic effect as GSK's Wellbutrin XL, when in reality, it entered the bloodstream at a much faster rate than the GSK drug...
To view the full article, register now.